A Novel Bivalent Vaccine Based on a PB2-knockout Influenza Virus Protects Mice from Pandemic H1N1 and Highly Pathogenic H5N1 Virus Challenges

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2013 May 10

PMID 23658445

Citations 14

Authors

Ryuta Uraki

Maki Kiso

Kiyoko Iwatsuki-Horimoto

Satoshi Fukuyama

Emi Takashita

Makoto Ozawa

Yoshihiro Kawaoka

Affiliations

Soon will be listed here.

Abstract

Vaccination is an effective means to protect against influenza virus. Although inactivated and live-attenuated vaccines are currently available, each vaccine has disadvantages (e.g., immunogenicity and safety issues). To overcome these problems, we previously developed a replication-incompetent PB2-knockout (PB2-KO) influenza virus that replicates only in PB2 protein-expressing cells. Here, we generated two PB2-KO viruses whose PB2-coding regions were replaced with the HA genes of either A/California/04/2009 (H1N1pdm09) or A/Vietnam/1203/2004 (H5N1). The resultant viruses comparably, or in some cases more efficiently, induced virus-specific antibodies in the serum, nasal wash, and bronchoalveolar lavage fluid of mice relative to a conventional formalin-inactivated vaccine. Furthermore, mice immunized with these PB2-KO viruses were protected from lethal challenges with not only the backbone virus strain but also strains from which their foreign HAs originated, indicating that PB2-KO viruses with antigenically different HAs could serve as bivalent influenza vaccines.

Citing Articles

Generation and Characterization of Single-Cycle Infectious Canine Influenza A Virus (sciCIV) and Its Use as Vaccine Platform.

Nogales A, Chiem K, Breen M, DeDiego M, Parrish C, Martinez-Sobrido L Methods Mol Biol. 2022; 2465:227-255.

PMID: 35118625 DOI: 10.1007/978-1-0716-2168-4_13.

Comparative Study of the Temperature Sensitive, Cold Adapted and Attenuated Mutations Present in the Master Donor Viruses of the Two Commercial Human Live Attenuated Influenza Vaccines.

Rodriguez L, Blanco-Lobo P, Reilly E, Maehigashi T, Nogales A, Smith A Viruses. 2019; 11(10).

PMID: 31658679 PMC: 6832241. DOI: 10.3390/v11100928.

The Quest for a Truly Universal Influenza Vaccine.

Jang Y, Seong B Front Cell Infect Microbiol. 2019; 9:344.

PMID: 31649895 PMC: 6795694. DOI: 10.3389/fcimb.2019.00344.

Novel Approaches for The Development of Live Attenuated Influenza Vaccines.

Blanco-Lobo P, Nogales A, Rodriguez L, Martinez-Sobrido L Viruses. 2019; 11(2).

PMID: 30813325 PMC: 6409754. DOI: 10.3390/v11020190.

Pregnancy and infection: using disease pathogenesis to inform vaccine strategy.

Vermillion M, Klein S NPJ Vaccines. 2018; 3:6.

PMID: 29423318 PMC: 5794984. DOI: 10.1038/s41541-017-0042-4.

References

Rimmelzwaan G, Fouchier R, Osterhaus A . Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol. 2007; 18(6):529-36. DOI: 10.1016/j.copbio.2007.11.002. View

Yamada S, Hatta M, Staker B, Watanabe S, Imai M, Shinya K . Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathog. 2010; 6(8):e1001034. PMC: 2916879. DOI: 10.1371/journal.ppat.1001034. View

Sakabe S, Ozawa M, Takano R, Iwastuki-Horimoto K, Kawaoka Y . Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res. 2011; 158(1-2):124-9. PMC: 3103651. DOI: 10.1016/j.virusres.2011.03.022. View

Benton K, Misplon J, Lo C, Brutkiewicz R, Prasad S, Epstein S . Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J Immunol. 2001; 166(12):7437-45. DOI: 10.4049/jimmunol.166.12.7437. View

Lambert L, Fauci A . Influenza vaccines for the future. N Engl J Med. 2010; 363(21):2036-44. DOI: 10.1056/NEJMra1002842. View

Dolgin E . Four-strain flu vaccines coming to a pharmacy near you. Nat Med. 2012; 18(4):471. DOI: 10.1038/nm0412-471. View

van der Wouden J, Bueving H, Poole P . Preventing influenza: an overview of systematic reviews. Respir Med. 2005; 99(11):1341-9. DOI: 10.1016/j.rmed.2005.07.001. View

Ozawa M, Victor S, Taft A, Yamada S, Li C, Hatta M . Replication-incompetent influenza A viruses that stably express a foreign gene. J Gen Virol. 2011; 92(Pt 12):2879-2888. PMC: 3352570. DOI: 10.1099/vir.0.037648-0. View

Song J, Wang B, Park K, van Rooijen N, Quan F, Kim M . Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One. 2011; 6(1):e14538. PMC: 3022578. DOI: 10.1371/journal.pone.0014538. View

10.

Girard M, Katz J, Pervikov Y, Palkonyay L, Kieny M . Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine. 2010; 28(42):6811-20. DOI: 10.1016/j.vaccine.2010.07.034. View

11.

Murakami S, Horimoto T, Mai L, Nidom C, Chen H, Muramoto Y . Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. J Virol. 2008; 82(21):10502-9. PMC: 2573193. DOI: 10.1128/JVI.00970-08. View

12.

Cox R, Brokstad K, Ogra P . Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 2004; 59(1):1-15. DOI: 10.1111/j.0300-9475.2004.01382.x. View

13.

DuBridge R, Tang P, Hsia H, Leong P, Miller J, Calos M . Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol. 1987; 7(1):379-87. PMC: 365079. DOI: 10.1128/mcb.7.1.379-387.1987. View

14.

Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M . In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009; 460(7258):1021-5. PMC: 2748827. DOI: 10.1038/nature08260. View

15.

Schultz-Cherry S, Jones J . Influenza vaccines: the good, the bad, and the eggs. Adv Virus Res. 2010; 77:63-84. DOI: 10.1016/B978-0-12-385034-8.00003-X. View

16.

Clements M, Betts R, Tierney E, Murphy B . Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 1986; 24(1):157-60. PMC: 268857. DOI: 10.1128/jcm.24.1.157-160.1986. View

17.

Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P . Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A. 1999; 96(16):9345-50. PMC: 17785. DOI: 10.1073/pnas.96.16.9345. View

18.

Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S . The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine. 2005; 24(17):3669-76. DOI: 10.1016/j.vaccine.2005.07.005. View

19.

Kida H, Brown L, Webster R . Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology. 1982; 122(1):38-47. DOI: 10.1016/0042-6822(82)90375-0. View

20.

Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C, Mitamura K . Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol. 2005; 43(8):4139-46. PMC: 1233980. DOI: 10.1128/JCM.43.8.4139-4146.2005. View